MAR

The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million

By

GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or the “Company”) has today resolved on a new issue of units with preferential rights for the Company’s existing shareholders amounting to approximately SEK 85 million before issue costs and excluding the potential capital contribution that […]

The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million Read More »

Isofol receives regulatory approval to initiate clinical study of arfolitixorin

By

GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in Germany, BfArM, has given their final approval for the initiation of the new clinical trial of the company’s drug candidate arfolitixorin. The study will initially be conducted in Germany, where patient recruitment will commence shortly.

Isofol receives regulatory approval to initiate clinical study of arfolitixorin Read More »

Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin

By

GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product patent application for arfolitixorin, submitted under the PCT (Patent Cooperation Treaty). If granted, the patent could significantly strengthen and prolong arfolitixorin’s intellectual property protection internationally. The information in

Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin Read More »

Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin

By

GOTHENBURG, Sweden, July 16, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies that support the dose-response relationship for arfolitixorin. These positive data further strengthen the hypothesis behind the design of the clinical Phase Ib/II study in patients with colorectal cancer that Isofol plans to conduct in collaboration

Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin Read More »

Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development

By

GOTHENBURG, Sweden, July 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that an external committee of experts has performed a post hoc per-protocol analysis of the clinical phase III study AGENT that shows new results in favor of arfolitixorin. These positive data, together with conclusions from earlier studies and analyses, strengthen

Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development Read More »

Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin

By

GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company has signed a collaboration agreement with the world-leading academic hospital Charité Universitätsmedizin in Berlin, and Professor Sebastian Stintzing, for the further clinical development of arfolitixorin. The collaboration includes strategic planning of the clinical development of arfolitixorin in

Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin Read More »

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

By

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical company Solasia Pharma K.K. (“Solasia”), has confirmed its continued strong commitment in the development of arfolitixorin. Solasia will contribute with its expertise and participate in defining the detailed design of the

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin Read More »

Isofol presents a clinical development plan for arfolitixorin

By

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy and clinical development program for the drug candidate arfolitixorin. The board and management, together with external experts, have evaluated the available data for arfolitixorin and decided to conduct a clinical phase I/II study to document

Isofol presents a clinical development plan for arfolitixorin Read More »

Isofol appoints Petter Segelman Lindqvist as new CEO

By

GOTHENBURG, Sweden, January 9, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company’s Board of Directors has appointed Petter Segelman Lindqvist as new Chief Executive Officer. He has extensive experience from leading roles in several international pharmaceutical companies and takes up the position with immediate effect. The information in the

Isofol appoints Petter Segelman Lindqvist as new CEO Read More »

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects

By

GOTHENBURG, Sweden, December 28, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received additional results from the laboratory tests conducted with arfolitixorin ahead of a potential decision on the drug candidate’s continued clinical development. The results show interesting supplementary effects of arfolitixorin in two of a total of

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects Read More »

Scroll to Top